Skin Graft
ProcedureEpidermization of the defect by applying a thin layer of autologous epidermis
NCT Number: NCT02090361
In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Transplants cause retractile scars, adherent to the deep plan, that may require revision surgery . Since a decade , dermal matrices are mainly used in burned skin centers . The collagen -elastin matrix has the advantage to set up in the same operation that the skin graft and contain elastic fibers , two assets which improve the results of skin grafting.
Objective:
Evaluation of the clinical efficacy of the addition of a dermal matrix to skin graft on Skin Foldability, at day 360.
Methodology:
This is a multicenter randomized study (CHU Caen , Amiens, Rouen and Lille)
Conduct of the study :
The transplant will be performed according to the protocol defined between inter -region surgeons. The implementation of the dermal matrix will be in the same surgical technique as thin skin graft ( group 1 ) or the thin skin graft will be performed alone ( group 2) time .
Evaluation Criteria Main : Skin Foldability ( Uf ) assessed grafted site will be compared to the opposite side ungrafted evaluated at Day 360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).
To achieve the main objective, it is planned to compare the ratio between Uf graft site and the opposite healthy site between two groups: skin + matrix graft , or skin graft only. Thus, the Wilcoxon test for independent samples will be used to settle bilateral formulation between the null hypothesis ( there is no difference between the two groups ) and the alternative hypothesis ( there is a difference between the two groups ) . In determining the overall risk of first species to 5% and the power of this test to detect the 90% expected under the alternative hypothesis difference should be the main criterion for evaluating at least 59 patients in each group so 118 patients total.
Prospect If the contribution of a dermal matrix in loss of skin substances improves skin pliability and reduces pain , functional and aesthetic sequelae grafts thin skin , the dermal matrix may be proposed as a complementary treatment in these indications.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
CHU d'Amiens, Amiens, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Epidermization of the defect by applying a thin layer of autologous epidermis
Time frame: Day 360
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).
Time frame: Day 180
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D180 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)
Time frame: Day 90
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D90 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)
Time frame: D7
Assessment of pain on the grafted site EVA at Day 7
Time frame: Day 15
Assessment of pain on the grafted site at Day 15
Time frame: Day 30
Assessment of pain at the grafted site EVA to D30
Time frame: Day 90
Assessment of pain at the grafted site EVA at D30
Time frame: Day 180
Assessment of pain at the grafted site EVA at Day 180
Time frame: Day 360
Assessment of pain at the grafted site EVA at Day 360
Time frame: Day 360
Occurrence within 360 days of a local complication requiring reoperation
Time frame: Day 7
Evaluation of the percentage of area healed at Day 7
Time frame: Day 15
Evaluation of the percentage of area healed at Day 15
Time frame: Day 30
Evaluation of the percentage of area healed at Day 30
Time frame: Day 30
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 30
Time frame: Day 90
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 90
Time frame: Day 180
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 180
Time frame: Day 360
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 360
Time frame: Day 90
Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 90
Time frame: Day 180
Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 180
Time frame: Day 360
Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 360
University Hospital, Rouen
Other
Acronym: MATRIGREFFE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04828304
Burn Wound, Burns
Gouda, Netherlands
View Trial DetailsNCT05646121
Arterial Ulcers, Cardiovascular Diseases
Bolesławiec, Poland
View Trial DetailsNCT05907915
Skin Graft
Giza, Egypt
View Trial DetailsNCT04754048
Acute Wound, Dehiscence
Ghent, Belgium
View Trial Details